Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024
VIEWPOINTS

Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots

Shots:  G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis  Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data  Philip further goes ahead to share details on VTAMA’s ongoing study…
February 29, 2024

Read more

News

Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

Shots:   The P-I clinical trial evaluates the safety & efficacy of RT-111 in delivering CT-P43 (biosimilar, ustekinumab) in patients with moderate to severe plaque psoriasis, active psoriatic arthritis & IBD  As per the results, RT-111 delivered CT-P43 in a dose proportional manner with high bioavailability & depicted a higher Cmax & shorter Tmax vs ustekinumab…
February 3, 2024

Read more

Insights+ Key Biosimilars Events of December 2023
INSIGHTS+

Insights+ Key Biosimilars Events of December 2023

Shots:  Stay up to date with PharmaShots Biosimilars Report, a monthly digest designed to keep you familiarized with the recent developments in biologics  Biosimilars are cost-effective alternatives to branded drugs but are very much alike when it comes to safety and efficacy  Check out the developments in the Biosimilars with PharmaShots’ illuminating report. PharmaShots has…
January 9, 2024

Read more

Insights+ Key Biosimilars Events of November 2023
INSIGHTS+

Insights+ Key Biosimilars Events of November 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During November, Amgen received US FDA approval for Wezlana, biosimilar of ustekinumab &…
December 6, 2023

Read more

Top Performing Drug – Enbrel (June Edition)
INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023

Read more

VIEWPOINTS_Daniel Quirk_2023
VIEWPOINTS

Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots: Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque Psoriasis He also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2 The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023

Read more

Exclusive_Stacey Williams_2023
EXCLUSIVE

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots: Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment The…
January 23, 2023

Read more

Load more